Publications

Ashley, D. M., A. Muscat, L. Rigby, and E. Algar. “EXPLORING THE FEASIBILITY OF EPIGENETIC THERAPIES FOR RHABDOID TUMOR.” In Neuro Oncology, 12:II36–II36. OXFORD UNIV PRESS INC, 2010.

Scholars@Duke

Partap, S., T. V. Hoc, T. T. Ha, and D. Ashley. “IDENTIFYING OBSTACLES IN TREATING CHILDREN WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS IN DEVELOPING COUNTRIES.” In Neuro Oncology, 12:II18–II18. OXFORD UNIV PRESS INC, 2010.

Scholars@Duke

Lei, Dapeng, Erich M. Sturgis, Li-E Wang, Zhensheng Liu, Mark E. Zafereo, Qingyi Wei, and Guojun Li. “FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck.” Cancer Epidemiol Biomarkers Prev 19, no. 6 (June 2010): 1484–91. https://doi.org/10.1158/1055-9965.EPI-10-0030.

PMID
20501759
Full Text

Tailor, Tina D., Gabi Hanna, Pavel S. Yarmolenko, Matthew R. Dreher, Allison S. Betof, Andrew B. Nixon, Ivan Spasojevic, and Mark W. Dewhirst. “Effect of pazopanib on tumor microenvironment and liposome delivery.” Mol Cancer Ther 9, no. 6 (June 2010): 1798–1808. https://doi.org/10.1158/1535-7163.MCT-09-0856.

PMID
20515941
Full Text

Armstrong, Andrew J., George J. Netto, Michelle A. Rudek, Susan Halabi, David P. Wood, Patricia A. Creel, Kelly Mundy, et al. “A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.” Clin Cancer Res 16, no. 11 (June 1, 2010): 3057–66. https://doi.org/10.1158/1078-0432.CCR-10-0124.

PMID
20501622
Full Text

Ostrander, JH, McMahon, CM, Lem, S, Millon, SR, Brown, JQ, Seewaldt, VL, and Ramanujam, N. "Optical redox ratio differentiates breast cancer cell lines based on estrogen receptor status." Cancer Res 70, no. 11 (June 1, 2010): 4759-4766.

PMID
20460512
Full Text

Khasraw, M., N. Pavlakis, S. McCowatt, C. Underhill, S. Begbie, P. de Souza, A. Boyce, et al. “Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer.” Ann Oncol 21, no. 6 (June 2010): 1302–7. https://doi.org/10.1093/annonc/mdp524.

PMID
19917571
Full Text

Armstrong, A. J., and D. J. George. “Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.” Prostate Cancer Prostatic Dis 13, no. 2 (June 2010): 108–16. https://doi.org/10.1038/pcan.2009.62.

PMID
20066005
Full Text

Khasraw, M., A. Townsend, T. Price, J. Hart, D. Bell, and N. Pavlakis. “Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours.” Intern Med J 40, no. 6 (June 2010): 453–58. https://doi.org/10.1111/j.1445-5994.2010.02245.x.

PMID
20636828
Full Text

Khasraw, M., L. E. Abrey, A. B. Lassman, A. Hormigo, C. Nolan, I. T. Gavrilovic, I. K. Mellinghoff, A. S. Reiner, L. M. DeAngelis, and A. M. Omuro. “Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV).” In Journal of Clinical Oncology, 28:2065–2065. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.2065.

Full Text

Pages